Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HMGCR | P04035 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL818454 | 0.83 | HMGCR (0.40) | GAAHMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL13623133 | 0.77 | TRPA1 (0.41) | GAA | |
| SCHEMBL27986214 | 0.75 | CES1 (0.38) | — | |
| SCHEMBL9015652 | 0.75 | ALDH1A1 (0.37) | GAAHMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL2178900 | 0.72 | HMGCR (0.52) | GAAHMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL13623137 | 0.72 | — | — | |
| SCHEMBL14282026 | 0.71 | HMGCR (0.36) | GAAHMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL13544793 | 0.70 | LMNA (0.38) | GAAHMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL9579482 | 0.70 | TET2 (0.34) | GAAHMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL12595360 | 0.70 | KMT2A (0.32) | GAAHMGCRCHRM1TBXA2RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916581-B2 | (S)-N-methylnaltrexone | PROGENICS PHARMACEUTICALS, INC. (US) | 2014-12-23 | — | — | US | disclosed |
| EP-1928882-B1 | (S)-N-METHYLNALTREXONE, PROCESS FOR ITS SYNTHESIS AND ITS PHARMACEUTICAL USE | PROGENICS PHARM INC (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20120136019-A1 | (S)-N-METHYLNALTREXONE | PROGENICS PHARMACEUTICALS, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| EP-2450360-A2 | (S)-N-Methylnaltrexone | Progenics Pharmaceuticals, Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| US-8003794-B2 | (S)-N-methylnaltrexone | PROGENICS PHARMACEUTICALS, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20100105911-A1 | (S)-N-methylnal trexone | ALBANY MOLECULAR RESEARCH, INC. | 2010-04-29 | — | — | US | disclosed |
| EP-2111108-A2 | (S)-N-STEREOISOMERS OF 7,8-SATURATED-4,5-EPOXY-MORPHINANIUM ANALOGS | Progenics Pharmaceuticals, Inc. (US) | 2009-10-28 | — | — | EP | disclosed |
| EP-2101773-A2 | (R)-N-STEREOISOMERS OF 7,8-SATURATED-4,5-EPOXY-MORPHINANIUM ANALOGS | Progenics Pharmaceuticals, Inc. (US) | 2009-09-23 | — | — | EP | disclosed |
| US-7563899-B2 | (S)-N-methylnaltrexone | PROGENICS PHARMACEUTICALS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-20090047279-A1 | (R)-N-Stereoisomers of 7,8-Saturated-4,5-Epoxy-Morphinanium Analogs | PROGENICS PHARMACEUTICALS, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2008136865-A9 | (S)-N-STEREOISOMERS OF 7,8-SATURATED-4,5-EPOXY-MORPHINANIUM ANALOGS | PROGENICS PHARM INC (US) | 2009-01-15 | — | — | WO | disclosed |
| WO-2008136865-A2 | (S)-N-STEREOISOMERS OF 7,8-SATURATED-4,5-EPOXY-MORPHINANIUM ANALOGS | PROGENICS PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| EP-1928882-A2 | (S)-N-METHYLNALTREXONE, PROCESS FOR ITS SYNTHESIS AND ITS PHARMACEUTICAL USE | PROGENICS PHARMACEUTICALS, INC. (US) | 2008-06-11 | — | — | EP | disclosed |
| WO-2008064351-A2 | (R)-N-STEREOISOMERS OF 7,8-SATURATED-4,5-EPOXY-MORPHINANIUM ANALOGS | PROGENICS PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20070265293-A1 | Opioid antagonists; lyophilization | PROGENICS PHARMACEUTICAIS, INC. | 2007-11-15 | — | — | US | disclosed |
| WO-2006127898-A2 | (S)-N-METHYLNALTREXONE, PROCESS FOR ITS SYNTHESIS AND ITS PHARMACEUTICAL USE | PROGENICS PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047279-A1 | (R)-N-Stereoisomers of 7,8-Saturated-4,5-Epoxy-Morphinanium Analogs | OPRM1, OPRK1, OPRD1 | GAA 3221/4885HMGCR 2688/4885CHRM1 79/4885 |
| US-20100105911-A1 | (S)-N-methylnal trexone | TSNAX, MTX1, MTX2 | GAA 3688/4885HMGCR 1229/4885CHRM1 1175/4885 |
| US-20070265293-A1 | Opioid antagonists; lyophilization | OPRM1, OGFR, OPRL1 | GAA 3064/4885HMGCR 4018/4885CHRM1 615/4885 |
| US-20120136019-A1 | (S)-N-METHYLNALTREXONE | OPRM1, OPRL1, LPXN | GAA 4086/4885HMGCR 2895/4885CHRM1 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.